Articles tagged with Drug Discovery
Researchers have identified a preclinical candidate that may slow the natural decline in memory associated with ageing. The new synthetic compound selectively blocks an enzyme involved in high levels of 'stress' steroid hormones, which are linked to memory loss.
Researchers at the University of Alberta have developed a drug that can reduce or eliminate airborne disease transmission when someone coughs. The new treatment uses a spray form and has shown promise in suppressing droplet emission from lung fluid.
Researchers have discovered that an enzyme called NOX4 produces hydrogen peroxide after a stroke, leading to nerve cell death. Inhibiting this enzyme with a new drug reduces brain damage and preserves brain functions in mice with stroke.
Researchers have discovered a novel compound that amplifies the effects of anandamide, a natural chemical in the body similar to THC found in marijuana. The synthetic drug URB937 inhibits FAAH enzyme, enhancing anandamide levels and producing analgesic effects without sedation or addiction.
The Open Source Drug Discovery (OSDD) Consortium is a worldwide scientific community working together to discover and develop new drugs. Key findings include the development of a comprehensive map of Mycobacterium tuberculosis genome, paving the way for a potential new drug for tuberculosis.
Two research teams discovered life-saving medications, JANUVIA for type 2 diabetes and CHANTIX for smoking cessation, enhancing people's ability to regulate blood sugar levels and reduce nicotine cravings. These treatments have helped millions worldwide, with CHANTIX being approved in 86 countries and over 7 million prescribed in the US.
A Yale team has discovered the secrets of a 'magic' antidepressant that can take effect in hours, rather than weeks or months. The study found that ketamine restores connections between brain cells damaged by chronic stress.
Researchers at the University of Strathclyde found that a substance called beeglue, originating from beehives in the Pacific region, was active against MRSA. The study isolated two compounds, Propolin C and Propolin D, which showed good activity against all MRSA strains tested.
A team of MIT chemists has designed a new way to attach trifluoromethyl groups to compounds, which could allow pharmaceutical companies to create and test new drugs faster and more efficiently. The new synthesis uses a palladium catalyst and achieved yields ranging from 70 to 94 percent.
Researchers at Neurocentre Magendie in Bordeaux found that addiction is caused by a persistent impairment of synaptic plasticity, leading to a permanent loss of the brain's ability to adapt and learn. This lack of plasticity results in compulsive consumption and loss of control over drug use.
The TB Alliance has made significant progress in developing new TB drugs, with three co-developed by the organization and its partners, and two others currently being tested through the Critical Path to TB Regimens (CPTR) initiative.
Researchers have discovered high-activity mutants of human butyrylcholinesterase that could be used to develop anti-cocaine medication. Additionally, a microbiocide-based HIV prevention measure holds promise for developing countries, particularly in sub-Saharan Africa.
Researchers have developed compounds that inhibit bacterial enzymes with longer residence times, correlating with improved in vivo activity. This discovery may lead to the development of agents for non-invasive bacterial imaging using positron emission tomography.
The Wellcome Trust extends its Seeding Drug Discovery initiative with a £110 million investment over five years. This support enables the progression of promising drug discovery projects to attract follow-on investors and develop novel medicines.
Scientists are developing new medications to block abnormal clumps of amyloid-beta protein in the brain, which may slow Alzheimer's disease progression. Clinical trials could lead to new treatments within 5-10 years if successful.
Scientists have identified a new approach to tackling human African trypanosomiasis (HAT), also known as sleeping sickness. A valid drug target has been found and leads for orally administered drugs have been identified, showing promise for effective treatment of the disease.
Researchers at Scripps Research Institute have discovered that the old drug closantel may be useful in combating river blindness by inhibiting the molting process of the parasite. This finding holds tremendous potential for the treatment of this neglected tropical disease, which affects over 37 million people.
A consortium of scientists, including top researchers from academic institutions and pharmaceutical companies, is developing new methods for drug discovery in depression and schizophrenia. The project aims to overcome bottlenecks such as lack of accurate animal models and symptom-based diagnostic categories.
Scientists at the University of Kentucky have discovered that withaferin A can simultaneously target two key proteins, vimentin and GFAP, implicated in reactive gliosis. This finding could lead to new treatments for diseases such as multiple sclerosis, Alzheimer's disease, stroke, and traumatic brain injury.
Researchers at McMaster University have developed a way to propel microscopic worms using an electric field, enabling high-throughput micro-screening devices for drug discovery. The technique demonstrates movement of worms forward and in reverse guided by the direction of the electric field, allowing for rapid screening of chemicals an...
Researchers at Emerald BioStructures have developed new allosteric small molecule modulators of phosphodiesterase-4 (PDE4) with improved safety and efficacy. These discoveries validate the company's structure-based drug design capabilities for addressing previously undruggable targets in inflammatory diseases and cognitive impairments.
Researchers found that antibiotic drugs can alter bacterial cell gene expression levels, leading to increased survival. The study suggests that antagonistic drug pairings can slow down the evolution of antibiotic resistance by restoring cellular equilibrium.
A new imaging technique developed by a team of researchers could lead to the discovery of new antibiotics, antifungal, antiviral, and anti-cancer drugs. The method uses mass spectrometry to analyze chemical communication between microorganisms.
Researchers at Johns Hopkins University discovered a 1930s gonorrhea medication, acriflavine, that can halt the growth of new blood vessels in cancer cells. By inhibiting HIF-1, a protein essential for tumor growth, acriflavine may one day be incorporated into chemotherapy cocktails to fight cancer.
A team of researchers from Pitt and Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection affecting millions worldwide. The newly developed strategy, called HILCES, uses high-throughput screening to identify effective drug candidates.
The Wellcome Trust has awarded €2.8 million to the Laboratory for Virology and Experimental Chemotherapy at K.U.Leuven to search for new treatments for dengue fever, a viral disease prevalent in tropical and subtropical regions. Researchers will collaborate with the pharmaceutical industry to develop medications for this deadly virus.
Researchers have developed a novel method to generate functional hepatocytes for drug testing, offering an unlimited and reliable source of liver cells. The new technique uses induced pluripotent stem cell technology to create hepatocytes from adult skin cells, overcoming the limitations of primary human hepatocytes.
Dabigatran, a new blood-thinner, has been shown to be as effective as warfarin in preventing strokes and major bleeding, but with significantly fewer side effects. This finding could lead to a change in standard anticoagulant therapy.
The CRIMALDDI project, led by Liverpool School of Tropical Medicine, aims to coordinate European and international antimalarial drug discovery efforts. The project will develop a prioritized roadmap and 5-year action plan to deliver on this roadmap.
SRI International was chosen to lead three research and development centers in the NCI's Chemical Biology Consortium program. The goal of the program is to discover and develop new cancer therapeutics against novel molecular and genetic targets.
Scientists have developed a more efficient method to produce a novel form of acetaminophen with reduced liver toxicity risk, offering a potential solution to the growing concern over the drug's effects.
Researchers found that quinine blocks cells' ability to take up essential amino acid tryptophan, leading to adverse side effects. Dietary tryptophan supplements may help alleviate these issues by improving quinine's effectiveness against malaria parasites.
Researchers at the University of Minnesota Medical School have made a breakthrough in understanding how the commonly prescribed drug praziquantel works to treat Schistosomiasis. Praziquantel causes two-headed organisms by subverting normal regeneration, leading to the identification of key molecules that control its effects.
Researchers have developed a low-cost strategy to discover new drugs for neglected diseases, utilizing global educational resources and distributed problem-solving. Students worldwide are synthesizing candidate molecules, meeting industry standards, and participating in the process.
Researchers identified an enzyme called Idol that destroys the LDL receptor, allowing more 'bad' cholesterol to circulate in the blood. By blocking Idol's activity, cells produce more receptors and absorb more cholesterol from the body.
Researchers at Johns Hopkins University School of Medicine have discovered a natural compound that can stop malaria parasite growth, interacting with the parasite's MetAP2 protein. The compound, fumarranol, was found to be less toxic than existing medications and showed promise in treating malaria in mice.
SRI International will screen a library of well-characterized drugs against the 2009 H1N1 influenza A virus. The project aims to identify new treatments with better efficacy and potency than current antiviral drugs. SRI's expertise in drug screening and development will help expedite the development of new therapies.
SRI International has received a $100,000 Grand Challenges Explorations grant to develop new antibiotics against antibiotic-resistant tuberculosis. The project aims to identify small organic molecule metabolites essential for bacterial growth and survival.
Researchers develop cheap and efficient method to identify small molecules for diabetes treatment, finding NAADP plays a crucial role in insulin secretion. This discovery could lead to a new class of drugs to treat type 2 diabetes.
Researchers at the University of Oxford have developed a cheap and efficient method to discover new drugs for type 2 diabetes. They identified a small molecule called Ned-19, which plays a crucial role in insulin secretion, representing a brand new target for diabetes drugs.
Researchers have discovered a drug that eases protein fusion, increasing learning capacity in mice with Alzheimer's disease. The treatment could offer new perspectives and alternatives to existing medications.
Researchers at Case Western Reserve University discovered a nanotechnology-based technique to block damaging gas transport through polymers, making them stronger and more efficient. This breakthrough has potential applications in food and medicine packaging, as well as electronic equipment protection.
Researchers at Monash University have made a breakthrough in treating malaria by deactivating the parasite's digestive machinery. The discovery could provide treatment for millions of people worldwide and offers hope against drug-resistant malaria.
Researchers at the University of Illinois Chicago have discovered compounds that show high antiparasitic activity against Leishmania parasite, which could potentially be modified to treat the disease. The new compounds are less toxic than miltefosine and can kill the parasite inside blood cells.
Biotech scientists are applying genomics technologies to toxicology research to better understand the effects of novel drug candidates. This trend towards predictive toxicogenomics aims to develop a new compound's mechanism of action and predict toxicity, with several companies and consortia already working on this technology.
A drug based on a garlic chemical, vanadium-allixin, reduces blood glucose levels in diabetic mice, offering promise as an oral treatment for diabetes. The study aims to test the drug in humans in future work.
Scientists from three universities will establish a new center to develop state-of-the-art chemical libraries, increasing the efficiency of compound synthesis. The center aims to identify new compounds for future drug development and basic biomedical research.
Researchers at Duke University Medical Center discovered that two common beta-blockers can stimulate a pathway that promotes cell survival and protects heart tissue. The study finds that alprenolol and carvedilol may have greater potential to repair the heart and prevent further damage.
Feldmann and Maini discovered tumor necrosis factor-alpha as an effective therapeutic target for rheumatoid arthritis and other chronic inflammatory conditions. Their research led to the development of several anti-TNF drugs, transforming treatment for people diagnosed with chronic inflammatory conditions.
Researchers found that uninsured patients were more likely to receive brand-name drugs after the clinic closed its drug sample closet, leading to increased costs. In contrast, Medicaid patients showed no significant change in generic prescribing despite the availability of free samples.
The American Chemical Society has inducted 25 scientists into its Heroes of Chemistry hall of fame, including Bruce Roth, inventor of Lipitor, the world's largest selling drug. The honorees are being recognized for their groundbreaking research and contributions to humanity.
The European Bioinformatics Institute (EMBL-EBI) will gain free access to large collections of information on drug properties and small molecules after receiving £4.7 million from the Wellcome Trust. This will enable academia to participate in early-stage drug discovery, potentially improving prediction of side effects.
Researchers developed a computational tool to compare drug side effects and predict common targets, revealing hidden therapeutic potential. The approach successfully identified new uses for marketed drugs in treating diseases they were not specifically developed for.
Researchers found that brightly colored beetles and butterfly larvae are significantly more common on plants with compounds active against certain diseases, such as breast cancer and malaria. This discovery could speed up drug discovery and provide insight into the ecological relationships between tropical-forest plants and insects.
Researchers at Fox Chase Cancer Center have discovered a small molecule that locks an essential enzyme in an inactive form, potentially leading to the development of new antibiotics. The discovery targets morpheeins, proteins made from individual components that can reconfigure themselves within living cells.
Gamma-secretase modulators, a class of agents in testing to treat Alzheimer's, work by reducing long Abeta peptides and increasing shorter ones that inhibit aggregation. This could lead to new treatments for the disease, with one such drug, tarenflurbil, showing promise in patients with mild Alzheimer's.
Researchers at North Carolina State University have successfully reinvigorated a failed HIV drug by adding gold nanoparticles, which enhances its binding capability and prevents the virus from gaining a foothold. This innovative approach offers new hope for treating HIV infection.
Companies like UCB Pharma and CeeTox are using cell-based assays to assess the toxic characteristics of small molecule compounds. This early identification can improve clinical trial results and reduce the time to market.
Researchers at Uppsala University have made a breakthrough in treating eating disturbances, including obesity and anorexia, by targeting the melanocortin system. The system regulates energy balance and appetite, and tiny imbalances can lead to major changes.
A clinical trial shows that romiplostim significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura (ITP), a hematologic disorder that can cause uncontrolled bleeding. The novel drug duplicates the action of a natural hormone discovered by MGH investigator, offering low toxicity and high response rates.